Nanomedicine for glaucoma: Sustained release latanoprost offers a new therapeutic option with substantial benefits over eyedrops

Drug Delivery and Translational Research

Volumn 4, Issue 4, 2014, Pages 303-309

  Wong, Tina T ^a,b,c   Novack, Gary D ^d   Natarajan, Jayaganesh V ^c   Ho, Ching Lin ^b   Htoon, Hla M ^a   Venkatraman, Subbu S ^c  

^a SINGAPORE EYE RESEARCH INSTITUTE   (Singapore)

^b SINGAPORE NATIONAL EYE CENTRE   (Singapore)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d PHARMALOGIC DEVELOPMENT INC   (United States)

Author keywords

Glaucoma; Human subjects; Liposomal latanoprost; Nanomedicine; Patient compliance; Sustained release

Indexed keywords

EYE DROPS; LATANOPROST; NANOCARRIER; NANOLIPOSOME; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLURRED VISION; CLINICAL ARTICLE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EYE DISCOMFORT; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; LIPOSOMAL DELIVERY; MALE; NANOMEDICINE; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; SUSTAINED RELEASE FORMULATION; TREATMENT OUTCOME;

EID: 84904502274     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-014-0196-9     Document Type: Article

References (20)

1. Resnikoff S, Pascolini D, Etya'ale D, Kocur I, Pararajasegaram R, Pokharel GP, et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004;82(11): 844-51.
2. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3): 262-7. doi: 10. 1136/bjo. 2005. 081224.
3. Robin AL, Novack GD, Covert DW, Crockett RS, Marcic TS. Adherence in glaucoma: objective measurements of once-daily and adjunctive medication use. Am J Ophthalmol. 2007;144(4): 533-40.
4. Stone JL, Robin AL, Novack GD, Covert DW, Cagle GD. An objective evaluation of eyedrop instillation in patients with glaucoma. Arch Ophthalmol. 2009;127(6): 732-6. doi: 10. 1001/archophthalmol. 2009. 96.
5. Tsai JC, McClure CA, Ramos SE, Schlundt DG, Pichert JW. Compliance barriers in glaucoma: a systematic classification. J Glaucoma. 2003;12(5): 393-8.
6. Camras CB, Hedman K. Rate of response to latanoprost or timolol in patients with ocular hypertension or glaucoma. J Glaucoma. 2003;12(6): 466-9.
7. Natarajan JV, Chattopadhyay S, Ang M, Darwitan A, Foo S, Zhen M, et al. Sustained release of an anti-glaucoma drug: demonstration of efficacy of a liposomal formulation in the rabbit eye. PloS One. 2011;6(9): e24513. doi: 10. 1371/journal. pone. 0024513.
8. Natarajan JV, Ang M, Darwitan A, Chattopadhyay S, Wong TT, Venkatraman SS. Nanomedicine for glaucoma: liposomes provide sustained release of latanoprost in the eye. Int J Nanomedicine. 2012;7 doi: 10. 2147/ijn. s25468.
9. Natarajan JV, Darwitan A, Barathi VA, Ang M, Htoon HM, Boey F, et al. Sustained drug release in nanomedicine: a long-acting nanocarrier-based formulation for glaucoma. ACS Nano. 2014. doi: 10. 1021/nn4046024.
10. Hughes BA, Bacharach J, Craven ER, Kaback MB, Mallick S, Landry TA, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0. 004%/timolol 0. 5% ophthalmic solution compared to travoprost 0. 004% ophthalmic solution and timolol 0. 5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertension. J Glaucoma. 2005;14(5): 392-9.
11. Scherer WJ. A retrospective review of non-responders to latanoprost. J Ocul Pharmacol Ther Off J Assoc Ocul Pharmacol Ther. 2002;18(3): 287-91.
12. Novack GD. Ophthalmic drug delivery: development and regulatory considerations. Clin Pharmacol Ther. 2009;85(5): 539-43. doi: 10. 1038/clpt. 2008. 297.
13. Zhang JA, Anyarambhatla G, Ma L, Ugwu S, Xuan T, Sardone T, et al. Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm. 2005;59(1): 177-87.
14. Kallinteri P, Antimisiaris SG, Karnabatidis D, Kalogeropoulou C, Tsota I, Siablis D. Dexamethasone incorporating liposomes: an in vitro study of their applicability as a slow releasing delivery system of dexamethasone from covered metallic stents. Biomaterials. 2002;23(24): 4819-26.
15. Liu JB, Lee H, Huesca M, Young AP, Allen C. Liposome formulation of a novel hydrophobic aryl-imidazole compound for anti-cancer therapy. Cancer Chemother Pharmacol. 2006;58(3): 306-18. doi: 10. 1007/s00280-005-0161-x.
16. Fahr A, van Hoogevest P, May S, Bergstrand N, Leigh MLS. Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. Eur J Pharm Sci. 2005;26(3-4): 251-65. doi: 10. 1016/j. ejps. 2005. 05. 012.
17. Moon JW, Song YK, Jee JP, Kim CK, Choung HK, Hwang JM. Effect of subconjunctivally injected, liposome-bound, low-molecular-weight heparin on the absorption rate of subconjunctival hemorrhage in rabbits. Invest Ophthalmol Vis Sci. 2006;47(9): 3968-74. doi: 10. 1167/iovs. 05-1345.
18. Chong RS, Su DHW, Tsai A, Jiang Y, Htoon HM, Lamoureux EL, et al. Patient acceptance and attitude toward an alternative method of subconjunctival injection for the medical treatment of glaucoma. J Glaucoma. 2011;22(3): 190-4. doi: 10. 1097/IJG. 0b013e318237c6c4.
19. Foo R, Lamoureux E, Wong R, Ho S-W, Chiang P, Rees G, et al. Acceptance, attitudes and beliefs of Singaporean Chinese towards an ocular implant for glaucoma drug delivery. Invest Ophthalmol Vis Sci. 2012. doi: 10. 1167/iovs. 12-10393.
20. Jampel HD, Schwartz GF, Robin AL, Abrams DA, Johnson E, Miller RB. Patient preferences for eye drop characteristics: a willingness-to-pay analysis. Arch Ophthalmol. 2003;121(4): 540-6. doi: 10. 1001/archopht. 121. 4. 540.